As of today (2024-05-01), the Forward Annual Dividend Yield of Zeo ScientifiX is 0.00%.
As of today (2024-05-01), the Trailing Annual Dividend Yield of Zeo ScientifiX is 0.00%.
ZEOX's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.5 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Zeo ScientifiX's Forward Dividend Yield %
For the Biotechnology subindustry, Zeo ScientifiX's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeo ScientifiX's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Zeo ScientifiX Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Zeo ScientifiX's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Zeo ScientifiX (Zeo ScientifiX) Business Description
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZEOX has been successfully added to your